Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation : results from the GARFIELD-AF registry
Pope, Marita Knudsen; Atar, Dan; Svilaas, Arne; Hole, Torstein; Nielsen, Jørn Dalsgaard; Hintze, Ulrik; Crisby, Milita; Raatikainen, Pekka; Airaksinen, K E Juhani; Virdone, Saverio; Pieper, Karen; Kayani, Gloria; Le Heuzey, Jean-Yves; Steffel, Jan; Stepinska, Janina; Bassand, Jean-Pierre; Camm, A John; Garfield-af Investigators (2021)
Pope, Marita Knudsen
Atar, Dan
Svilaas, Arne
Hole, Torstein
Nielsen, Jørn Dalsgaard
Hintze, Ulrik
Crisby, Milita
Raatikainen, Pekka
Airaksinen, K E Juhani
Virdone, Saverio
Pieper, Karen
Kayani, Gloria
Le Heuzey, Jean-Yves
Steffel, Jan
Stepinska, Janina
Bassand, Jean-Pierre
Camm, A John
Garfield-af Investigators
2021
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202201221529
https://urn.fi/URN:NBN:fi:tuni-202201221529
Kuvaus
Peer reviewed
Tiivistelmä
AIMS: The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries. METHODS: We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries. RESULTS: A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0-1 (72.8% vs 60.3%), 2-3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11-4.23) vs 4.08 (3.91-4.26), p value = .147] and [0.98 (0.73-1.32) vs 1.02 (0.93-1.11), p value = .819], while major bleeding was significantly higher [1.66 (1.32-2.09) vs 1.01 (0.93-1.10), p value < .001]. CONCLUSION: Nordic patients had significantly higher major bleeding than Non-Nordic-European patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE were comparable. CLINICAL TRIAL REGISTRATION: Unique identifier: NCT01090362. URL: http://www.clinicaltrials.gov. KEY MESSAGE: Nordic countries had significantly higher major bleeding than Non-Nordic-European countries. Rates of mortality and non-haemorrhagic stroke/SE were similar .
Kokoelmat
- TUNICRIS-julkaisut [16944]